This study focuses on patients with advanced non-small cell lung cancer (NSCLC) that is ALK-positive. ALK-positive means the cancer has a specific genetic change in the anaplastic lymphoma kinase gene. The study compares two medications: an experimental drug called NVL-655 and an approved medication called Alecensa (alectinib). These medications belong to a group of drugs called ALK inhibitors, which target the specific genetic change found in this type of lung cancer.

The purpose of this research is to evaluate how well NVL-655 works compared to Alecensa in patients who have not received any previous treatment for their advanced lung cancer. Both medications are taken by mouth in the form of tablets or capsules. The study will measure how long patients live without their cancer getting worse and track any side effects that may occur during treatment.

During the study, participants will be randomly assigned to receive either NVL-655 or Alecensa. The treatment may continue for up to several years, depending on how well it works for each patient. Throughout the study, patients will have regular medical check-ups and imaging scans to monitor their cancer. The study will also look at how the treatments affect patients’ quality of life and whether the medications work on cancer that has spread to the brain.